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Age-related neuronal dysfunction can be overcome by circulating factors present in
young blood. Growth differentiation factor-11 (GDF-11), a systemic factor that declines
with age, can reverse age-related dysfunction in brain, heart and skeletal muscle. Given
that age increases susceptibility to stroke, we hypothesized that GDF-11 may be directly
protective to neurons following ischemia. Primary cortical neurons were isolated from
E18 Wistar rat embryos and cultured for 7–10 days. Neurons were deprived of oxygen
and glucose (OGD) to simulate ischemia. Neuronal death was assessed by lactate
dehydrogenase, propidium iodide or CellToxTM green cytotoxicity assays. 40 ng/mL
GDF-11 administration during 2 h OGD significantly increased neuronal death following
24 h recovery. However, GDF-11 pre-treatment did not affect neuronal death during 2 h
OGD. GDF-11 treatment during the 24 h recovery period after 2 h OGD also did not
alter death. Real-time monitoring for 24 h revealed that by 2 h OGD, GDF-11 treatment
had increased neuronal death which remained raised at 24 h. Co-treatment of 1µM
SB431542 (ALK4/5/7 receptor inhibitor) with GDF-11 prevented GDF-11 neurotoxicity
after 2 h OGD and 24 h OGD. Transforming growth factor beta (TGFβ) did not increase
neuronal death to the same extent as GDF-11 following OGD. GDF-11 neurotoxicity was
also exhibited following neuronal exposure to hydrogen peroxide. These results reveal
for the first time that GDF-11 is neurotoxic to primary neurons in the acute phase of
simulated stroke through primarily ALK4 receptor signaling.
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INTRODUCTION
The increased life expectancy of twenty-first century living has led to a substantial rise in the
number of age-related disorders including stroke. Even in the thrombectomy era where a number of
ischemic stroke patients are receiving reperfusion therapy (either pharmacologically with alteplase
or mechanically via thrombectomy), the majority of ischemic stroke patients are left with no
therapeutic options acutely to limit the damage of ischemia (1). The search continues for both
primary and adjunctive neuroprotective therapies that can protect the brain from the resulting
injury following an ischemic stroke (2).
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Anti-aging factors are hypothesized to slow down the aging
process and improve the quality of life of the aged. Recently,
it was revealed that age-related neuronal dysfunction can be
overcome by circulating factors present in young blood (3).
A number of factors exist in young blood that are not found in
old blood. One of these factors, considered to be an anti-aging
factor is growth differentiation factor-11 (GDF-11) as its levels in
blood decline with age (4), though this has been challenged due
to problems with detection methods for GDF-11 measurement
(5). In addition, systemic (i.p.) administration of recombinant
GDF-11 has been shown to reverse age-related dysfunction in
the rodent brain (4), heart (6) and skeletal muscle (7). GDF-11
is a growth factor that belongs to the transforming growth factor-
beta (TGFβ) family and acts upon a number of TGFβ receptors
including ALK4 and ALK5 (8). Previous studies have shown
that TGFβ receptor agonists show neuroprotection whereas
TGFβ receptor antagonists have exacerbated injury in pre-clinical
stroke models (9). Two recent studies have trialed GDF-11 as
a neuroprotectant in middle cerebral artery occlusion models,
and both showed that recombinant GDF-11 administration
reduced neurobehavioural deficits through the augmentation of
angiogenesis, endothelial cell proliferation and increased neural
precursor proliferation out to 14 days post-stroke (10, 11).
Further evidence supporting this was the fact that SB431542,
a ALK4/5/7 receptor inhibitor, blocked the protective effects of
GDF-11 (10, 11).
Given its effectiveness on the vascular system and the ability
of GDF-11 to modulate age-related neuronal dysfunction, we
hypothesize that GDF-11 could be an ideal candidate as a
neuroprotective agent for ischemic stroke. Therefore, in this
study, we sought to determine whether GDF-11 administration
to primary neurons could provide direct protection to neurons
using an in vitromodel of ischemia.
MATERIALS AND METHODS
To determine the effects of GDF-11 directly on neurons, we
used a primary cortical neuronal culture as we have previously
described (12, 13). Neurons were plated onto poly-D-lysine-
coated 12 well plates at 105 cells per well in complete
neurobasal media containing 2% B27 serum-free supplement,
2mM L-glutamine and 1% penicillin/streptomycin in neurobasal
medium (all Invitrogen). Neurons remained in culture for 7–10
days to allow neuronal networks to develop before experiments
were conducted.
GDF-11 was purchased from Peprotech (cat#120-11, UK). To
determine whether GDF-11 altered basal viability of neurons,
GDF-11 was diluted in complete neurobasal media to produce
a concentration range of 4–400 ng/mL and added to neuronal
cultures for 48 h. Neuronal viability was assessed with a CellTiter
96 assay (Promega, UK) following manufacturer’s instructions,
with neurons being incubated for 5 h with the reaction reagent.
To determine whether GDF-11 altered neuronal viability
under simulated ischemic conditions, we performed OGD
experiments. Days in vitro (DIV) 7–10 primary cortical neurons
were exposed to 0% oxygen using a hypoxic chamber (Coy)
coupled with glucose-free neurobasal media (Invitrogen) for 2 h
as described previously (12, 13), or using an environmentally-
controlled microplate reader (Omega, BMG Labtech) for
up to 24 h exposure. Following 2 h OGD in the hypoxic
chamber, cultures were returned to normoxic conditions with
glucose-containing neurobasal media for 24 h. For all OGD
experiments, 40 ng/mL GDF-11 was used due to this being the
concentration in which effects in brain capillary endothelial
cells have been observed (4) and there was no neurotoxicity
under normoxic conditions (Figure 1A). Depending on the
experiment, GDF-11 was administered for 7 days prior to
OGD, during OGD or for 24 h following OGD in the
recovery phase.
To assess neuronal death, a lactate dehydrogenase (LDH)
activity assay (Cytotoxicity kit, Promega, UK), propidium
iodide assay or CellToxTM green cytotoxicity assay (Promega,
UK) was used as per manufacturer’s instructions. Briefly, for
the LDH assessment, media were collected at the end of
the relevant period for measurement of LDH release. The
cells were then lysed with 1% Triton X-100 in complete
neurobasal medium to obtain total LDH released. To get a
percentage cell death, the LDH released during the relevant
period was divided by the sum of the LDH released during
that period and during cell lysis (12, 13). For the propodium
iodide assay, cells were plated in 96-well plates at 50,000
cells/well and following the OGD protocol, propidium iodide
(final concentration 50µM, Invitrogen, UK) was added and
incubated for 30min. Plates were then assessed for the level
of cell death as indicated by propidium iodide fluorescence
(excitation 540 nm emission 620 nm) using a fluorometer
(Omega Optima, BMG Labtech, UK). The CellToxTM green
cytotoxicity assay was used per manufacturer’s instructions
for real-time monitoring of cell death as it measures cell
free DNA in the media or DNA of dead cells with a
compromised plasma membrane (14). After administration of
the CellToxTM Green reagent, and placed in the environmentally
controlled plate reader (Omega, BMG Labtech), a gas permeable
membrane (Breathe-Easy sealing membrane, Sigma) was used
to prevent evaporation while still allowing gas exchange.
A concurrent positive control was performed using lysis
buffer (Promega).
Neurons possess ALK4 and ALK5 receptors (15, 16),
and so to determine whether the effects of GDF-11
were mediated by the ALK4/5 receptors on neurons, we
performed neuronal OGD experiments in the presence of
GDF-11 with or without 1µM SB431542 (an ALK4/5/7
receptor inhibitor, Tocris) (17). TGFβ is a ligand for ALK5
receptors (15, 18) and so we performed neuronal OGD
experiments with 10 ng/mL TGFβ to determine its effect
on neurotoxicity.
During ischemia, neurons were exposed to a number of
potentially damaging factors including lack of energy supply,
oxidative stress and excitotoxicity. We exposed cortical neuronal
cultures to 100µM iodoacetate (to inhibit glycolysis) and
10µM antimycin A (to inhibit mitochondrial respiration) as
a model of chemical ischemia, 500µM glutamate as a model
of excitotoxicity, and 1mM hydrogen peroxide as a model
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FIGURE 1 | GDF-11 increased neuronal death during OGD. (A) Cortical neurons kept under normoxic conditions were exposed to GDF-11 (4–400 ng/mL) for 48 h.
Percentage neuronal viability was quantified with the CellTiter 96 assay. N=4 for each condition. 2 h OGD (B) and 2 h OGD + 24 h recovery (C) increased cortical
neuronal death compared to normoxia while GDF-11 increased cell death compared with media and DMSO under OGD conditions. GDF-11 did not affect neuronal
death under normoxic conditions. Cell death was quantified by LDH assay. Groups: media (control) (n = 6), DMSO (control) (n = 6), GDF-11 (n = 3). (D) GDF-11
increased cell death following 2 h OGD + 24 h recovery, but not under normoxia conditions using a propidium iodide assay. N = 8–16 per condition. All data are
presented as mean ± SEM. Two-way ANOVA with Tukey’s post-hoc Test. *p < 0.05, **p < 0.01, ****p < 0.0001.
of oxidative stress for 24 h. Experiments were carried out
in the absence or presence of GDF-11. Neuronal death was
determined by LDH activity of the incubating media during
the insults.
Data were analyzed by a two way ANOVA followed by
a Tukey’s post-hoc test when there were two independent
variables or a one way ANOVA followed by a Tukey’s or
Bonferroni’s post-hoc test when there was only one variable.
All analyses were performed using GraphPad Prism v7.0.
Data are presented as mean + SEM. All results are from at
least three experiments, p < 0.05 is considered statistically
significant. All data and research materials are available
upon request.
RESULTS
48h GDF-11 Administration Did Not Alter
Cellular Viability in Primary Cortical
Neurons
Initially, we wished to test whether GDF-11 altered neuronal
viability under standard culture conditions. Exposure of
4–400 ng/mL GDF-11 to neurons for 48 h did not affect
neuronal viability (all concentrations had >90% viability;
Figure 1A). Since Katsimpardi et al. had previously
shown effects of 40 ng/mL GDF-11 in brain capillary
endothelial cells (4), we selected this concentration for
subsequent studies.
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FIGURE 2 | GDF-11 had no effect on neuronal death with treatment prior to OGD and after OGD. (A) 7 days pre-treatment with 40 ng/mL GDF-11 had no effect on
cortical neuronal death during 2 h normoxia or OGD. GDF-11 was not present during the OGD phase. (B) 7 days pre-treatment with 40 ng/mL GDF-11 did not affect
cortical neuronal death following 2 h normoxia or OGD and 24 h recovery. GDF-11 was not present during the OGD phase. (C) Treatment with GDF-11 during 24 h
recovery only did not affect cortical neuronal death following 2 h normoxia or OGD. GDF-11 was not present during the OGD phase. Cell death was quantified by LDH
assay. Data presented as mean ± SEM. Groups: control (n = 6), DMSO (n = 3) and GDF-11 (n = 3). Two-way ANOVA with Tukey’s post-hoc test.
Exposure of 40ng/mL GDF-11 to Neurons
During 2h OGD Exacerbated Neuronal
Death
Given the potential neuroprotective effects of GDF-11 (10,
11), we wished to determine whether GDF-11 could provide
direct neuroprotection to ischemic neurons. Following 2 h OGD
(Figure 1B), there was a significant increase in cell death during
OGD compared to normoxia [F(1,48) = 201.7, p < 0.0001] as
detected by an LDH assay. Administration of 40 ng/mL GDF-11
to neurons during 2 h OGD significantly increased neuronal
death (vehicle: 19.3% ± 1.9% cell death, GDF-11: 33.9% ±
2.3%; Tukey’s p < 0.0001). At 24 h recovery following 2 h OGD
(Figure 1C), the OGD group continued to have significantly
increased cell death compared to normoxia [F(1, 48) = 111.1,
p < 0.0001], with GDF-11 increasing cell death compared to
OGD alone (vehicle: 37.3% ± 1.9% cell death, GDF-11: 51.7%
± 2.6%; Tukey’s p = 0.0019). This neurotoxicity by GDF-11
following OGD was replicated using a propidium iodide assay
(1.14 ± 0.04 fold over control, Tukey’s p = 0.003; Figure 1D).
There was no significant effect of GDF-11 treatment on neuronal
death under normoxic conditions (Figure 1).
GDF-11 Treatment Prior to OGD or After
OGD Did Not Alter Neuronal Death
Given that GDF-11 administration to ischemic neurons
worsened cell death, we then carried out experiments to
determine whether treatment with GDF-11 prior to OGD or
after OGD could alter this neurotoxic effect. Again, there was
a significant increase in cell death with OGD compared to
normoxia [Figure 2A, F(1,36) = 17.0, p = 0.0002]. However,
7 days of pre-treatment with GDF-11 did not affect neuronal
death during 2 h OGD compared to vehicle pre-treatment
(vehicle: 11.0% ± 3.3%, GDF-11: 11.1% ± 1.7%; Tukey’s
p = 0.998). Similar results were observed at 24 h recovery
following 2 h OGD (Figure 2B; vehicle: 28.7% ± 4.0%, GDF-11:
28.4% ± 2.4%; Tukey’s p = 0.998). When measuring cell death
during 24 h recovery after 2 h OGD or normoxia (Figure 2C),
there was a small but significant increase in neuronal death
following OGD [F(1,48) = 11.1, p = 0.0017]. When GDF-11 was
administered during the 24 h recovery period only following 2 h
OGD (Figure 2C), there was no significant effect of GDF-11
treatment on the ability of OGD to kill neurons (vehicle: 17.9%
± 1.7%, GDF-11: 17.2% ± 1.6%; Tukey’s p = 0.970). GDF-11
treatment had no effect on neuronal death at any timepoint
following normoxia (Figure 2).
Increase in Ischemic Neuronal Death by
GDF-11 Could Be Blocked by an ALK4/5
Receptor Inhibitor
GDF-11 caused neurotoxicity when administered during OGD
and so we sought to identify a mechanism by which this is
occurring. Neurons are known to possess a range of TGFβ
receptors including ALK4/5 receptors (15, 16) and GDF-11 is
known to bind to these receptors (8). We exposed OGD neurons
to GDF-11 in the presence or absence of SB431542, an ALK4/5/7
receptor inhibitor (17), and performed real-time monitoring
of cell death under OGD or normoxic conditions over a 24 h
period (Figures 3A,D). After 2 h OGD (Figure 3E), GDF-11
treatment had increased neuronal death (GDF-11: 1.27 ± 0.03
fold over control; vehicle: 1.15 ± 0.02 over control; Tukey’s
p = 0.0258) which remained raised at 24 h (Figure 3F; GDF-
11: 1.36 ± 0.08 fold over control; vehicle: 1.11 ± 0.01 fold over
control; Tukey’s p < 0.0001). Co-treatment of 1µM SB431542
with GDF-11 prevented GDF-11 neurotoxicity after 2 h OGD
(1.03 ± 0.04 fold over control; Tukey’s p < 0.0001) and 24 h
OGD (1.00 ± 0.04 fold over vehicle, Tukey’s p < 0.0001). No
significant effects with GDF-11 nor SB431542 were observed
during normoxic conditions (Figures 3B,C). We replicated this
experiment using the LDH assay (Figure 4A) and showed that
the addition of SB431542 to GDF-11 could restrict cell death
(0.72 ± 0.05 fold under control) compared to GDF-11 alone
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FIGURE 3 | GDF-11 neuronal toxicity during OGD was prevented by a ALK4/5/7 receptor inhibitor. (A) GDF-11 +/− SB431542 (ALK4/5/7 receptor inhibitor) had no
effect on neuronal death during 24 h of normoxia. (B) At 2 h of normoxia, there was no effect of GDF-11 on neuronal death. (C) At 24 h of normoxia, GDF-11 did not
affect neuronal death. (D) GDF-11 enhanced cortical neuronal death throughout 24 h of OGD which was prevented fully by the administration of SB431542. (E) At 2 h
OGD, GDF-11 increased neuronal death which was reversed by SB431542. (F) At 24 h OGD, GDF-11 increased neuronal death which was reversed by SB431542.
Cell death was measured by the CellToxTM Green Assay. Data presented as mean ± SEM. n = 3 per group except media control which was n = 6. One-way ANOVA
with Tukey’s post-hoc test. *p < 0.05; **p < 0.01; ***p < 0.001.
(1.28 ± 0.08, Bonferroni’s p = 0.0017) following 2 h OGD
+ 24 h recovery. We also assessed whether administration of
TGFβ could replicate the neurotoxicity exhibited by GDF-11
following OGD. Figure 4A demonstrated that while GDF-11
increased cell death compared to control (1.28 ± 0.08 fold
over control, Bonferroni’s p = 0.0743), TGFβ had no significant
effect compared to control (1.18 ± 0.06 fold over control,
Bonferroni’s p= 0.349).
GDF-11 Worsened Neuronal Viability
During Oxidative Stress but Not Chemical
Ischemia or Excitotoxicity
Other types of stressors occur during an ischemic injury
to the brain such as a lack of energy supply, excitotoxicity
and oxidative stress all of which can impact on neuronal
survival. We modeled these conditions in vitro to determine
whether GDF-11 could also alter neuronal death under these
conditions (Figure 4B). Exposure of neurons for 24 h to a
combination of 100µM iodoacetate (glycolysis inhibitor) and
10µM antimycin A (mitochondrial respiration inhibitor) to
mimic a reduction in energy supply led to increased neuronal
death (control: 8.0% ± 1.0%, iodoacetate/antimycin: 22.0% ±
0.9%; Tukey’s p< 0.0001), but this was not influenced by GDF-11
administration (iodoacetate/antimycin + GDF-11: 23.4% ±
1.0%, Tukey’s p = 0.9812). Neurons that were subjected to
500µM glutamate had increased neuronal death (control: 8.0%
± 1.0%, glutamate: 17.2%± 0.7%; Tukey’s p= 0.0032), but again
this was not influenced by GDF-11 administration (glutamate +
GDF-11: 20.5% ± 2.2%, Tukey’s p = 0.5455). 1mM hydrogen
peroxide indicative of oxidative stress showed a substantial
increase in neuronal death (control: 8.0%± 1.0%, H2O2: 55.3%±
1.3%; Tukey’s p < 0.0001), and interestingly GDF-11 exacerbated
neuronal death by hydrogen peroxide (H2O2 + GDF-11: 64.0%
± 2.0%, Tukey’s p= 0.0005).
DISCUSSION
The aging brain is susceptible to a number of different stressors,
and the effect of ischemia on the aged brain can cause
irreversible damage and subsequent mortality. Recent studies
have pointed toward factors that are present in young blood
such as GDF-11, that could have potential neuroprotective
effects (4, 10, 11). Circulating GDF-11 levels have been shown
to decrease with age (4, 6, 19), though this is controversial
(5, 20), but this could leave the brain in a susceptible state.
Here, we wished to determine whether GDF-11 could have
direct protective effects on neurons under simulated ischemic
conditions. On the contrary, we discovered that GDF-11 had
neurotoxic effects when administered during OGD, and that
this neurotoxicity appeared to be due to its activation of the
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FIGURE 4 | GDF-11 neuronal toxicity occurred under OGD and oxidative stress. (A) Neurons were exposed to 2 h OGD followed by 24 h recovery. GDF-11 increased
neuronal death while TGFβ did not increase death to the same extent. GDF-11 neurotoxicity was blocked by the ALK4/5/7 inhibitor SB431542. (B) Exposure to
chemical ischaemia (iodoacetate + antimycin A), excitotoxicity (glutamate) and oxidative stress (H2O2) for 24 h enhanced neuronal death. GDF-11 increased neuronal
death only during oxidative stress (H2O2) exposure. Data presented as mean ± SEM and were calculated from an LDH assay. n = 3–8 per group. One-way ANOVA
with Bonferroni post-hoc test. *p < 0.05, **p < 0.01, ***p < 0.001.
ALK4/5 receptors. GDF-11 neurotoxicity was also observed
under oxidative stress conditions. Confining GDF-11 to the
bloodstream will help prevent any direct neurotoxic effects of
GDF-11 under ischemic conditions.
Under normal conditions, GDF-11 is found in the
bloodstream, with a limited amount crossing an intact blood-
brain barrier (21). GDF-11 has been shown to have multiple
beneficial effects on the vasculature including promotion of
angiogenesis, maintaining the blood-brain barrier and providing
vascular stability (4, 10, 11, 21). Under in vivo stroke conditions,
GDF-11 has been shown to reduce infarct volume and improve
behavioral outcomes mainly due to both angiogenesis and
endothelial cell proliferation (10, 11). However, our evidence
suggests that if GDF-11 made it out of the bloodstream and
into the brain during ischemia, either through BBB leakage or
via some mode of active transport, then it could potentially be
harmful to neurons. Therefore, limiting the amount of neuronal
exposure to GDF-11 during a stroke could restrict its neurotoxic
effects while maintaining their vasculoprotective effects to help
improve recovery of the brain.
It is important to note that there was no indication that
GDF-11 was neurotoxic under normoxic conditions suggesting
that this neurotoxicity was only present when neurons were
exposed to ischemia. Likewise, experiments where GDF-11
administration took place prior to or after OGD did not
affect neuronal death. This indicates that the susceptibility of
neurons to GDF-11-induced neurotoxicity is during ischemia
only, but the effects of this can last during the recovery phase.
The mechanisms behind why this occurs are unclear, however
RNAseq data showed that primary hippocampal neurons subject
to OGD increased the expression of both the ALK4 receptor and
Smad3 (22). This suggests that the neurotoxic effects of GDF-
11 are limited to when the cell becomes stressed, which may
augment the activation of the ALK4/Smad3 signaling cascade
in neurons.
The type of stress that leads to GDF-11 neurotoxicity is
important as there are multiple stressors that can occur during
an ischemic episode in vivo. Our results suggest that when
neurons are oxygen and glucose deprived (limiting energy
substrates) and are exposed to oxidative stress (hydrogen
peroxide), then GDF-11-induced neurotoxicity ensues, whereas
under excitotoxic (excessive glutamate) and chemical ischemia
(limiting energy production), GDF-11 neurotoxicity was not
observed. However, a recent study showed that under conditions
where oxidative stress was increased such as in intracerebral
hemorrhage among other pathologies, administration of GDF-
11 intraperitoneally promoted production of heme oxygenase-1,
an important antioxidant, as well as protecting mitochondrial
capacity suggesting indirect effects on neuronal survival (23).
This highlights important differences between in vitro modeling
of neurons and how neuronsmay react to a stressor in vivo, which
can be influenced by different cell types in the brain which are not
present in single cell type cultures.
GDF-11 is a member of the TGFβ signaling family and
has been shown to act at specific TGFβ superfamily receptors
including ALK4 and ALK5 (8, 18). Both of these receptors are
expressed in neurons and can be activated by Activin A and
TGFβ1, respectively (15, 18, 24). Previous studies using Activin
A as an agonist at ALK4 receptors and TGFβ1 as an agonist
at ALK5 receptors have shown neuroprotective properties in in
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vivo models of stroke (9, 25). While our data showing direct
GDF-11 neurotoxicity under ischemic conditions is in contrast
to the neuroprotective effects of these agonists, the exposure
of TGFβ1 to neurons subjected chronically to glutamate led to
neurotoxicity (26). Our data suggest that GDF-11 neurotoxicity
was due to its action on the ALK4 receptor. TGFβ administration
(which only activates ALK5 receptors) did not increase neuronal
death to the same extent as GDF-11. This is further supported
by the evidence that the ALK4/5/7 inhibitor SB431542 could
block the neurotoxic effects of GDF-11 during OGD. Moreover,
RNAseq analysis of hippocampal neurons following OGD and
recovery has demonstrated that there was an increase in both
ALK4 receptor expression and Smad3 signaling following OGD
(22). Therefore, GDF-11 administrationmay put greater stress on
the Smad signaling cascade through ALK4 activation leading to
detrimental outcomes to neurons.
Exposure of hydrogen peroxide to neurons led to exacerbation
of neuronal death by GDF-11 which suggests that free radical
formation may be an important mechanism of cell death
by GDF-11. OGD of neuronal cultures can directly lead to
reactive oxygen species generation, which can be blocked by free
radical scavengers (27). Interestingly, a traditional pro-survival
factor, neurotrophin-3, unexpectedly showed damaging effects
on neurons following OGD due to increased reactive oxygen
species formation (28). Furthermore, there is evidence in other
disease conditions that activation of TGFβ and Smad signaling
can lead to reactive oxygen species formation (29). Confirmation
with pharmacological studies, using agents such as SB431542,
would be valuable to confirm that these effects are mediated
through the ALK4/5 receptors. Overall, there appears to be a link
between the TGFβ signaling cascade and free radical formation,
which could mediate GDF-11 neurotoxicity under ischemic and
oxidative stress conditions, but further experiments investigating
mitochondrial changes by GDF-11 under these conditions are
needed to confirm these effects.
There are some limitations to this study. One limitation was
the utilization of only one concentration of GDF-11 in the
neurotoxicity experiments (40 ng/mL). We showed that GDF-
11 at a range of concentrations (4–400 ng/mL) had no effects
on neuronal viability under normoxic conditions, and so we
carefully chose a concentration within this range that had
exhibited effects in previous studies (4) and had a concentration
above the half maximal effective concentration (EC50) to activate
Smad signaling in other cell types (30). However, we cannot rule
out the possibility that effects, beneficial or neurotoxic, could
be observed at other concentrations of GDF-11 following OGD.
Another limitation is that the isolated neuronal culture method
may not reflect the effects of GDF-11 in the complex brain
environment. However, determining direct effects of GDF-11 on
neurons in vivo or in ex vivo brain slices is difficult, particularly
due to the strong vascular effects that GDF-11 are known to
have (4, 10, 11, 21), meaning that the viability of neurons will
be influenced by the effects of GDF-11 on other cell types in
experiments using these methodologies.
These results reveal for the first time that GDF-11 is
neurotoxic to primary neurons in the acute phase of simulated
stroke through primarily ALK4 receptor signaling. Therefore,
limiting GDF-11 access to the brain during ischemia could
prevent its neurotoxicity. Future studies will further characterize
the neurotoxic vs. protective properties of GDF-11 in the brain
and whether the protection of the brain is solely mediated
through the vascular system.
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